Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphodiesterase type 5A (PDE5A) is an enzyme that selectively hydrolyzes cyclic guanosine monophosphate (cGMP), converting it into inactive 5’ GMP. This action regulates intracellular levels of cGMP, which plays a central role in various physiological processes including vasodilation, smooth muscle relaxation, neurotransmission, calcium homeostasis, and retinal phototransduction. Selective inhibitors of PDE5A are widely used drugs for erectile dysfunction and pulmonary arterial hypertension.
Selective inhibitors of PDE5A prolong penile erection via increased local blood flow and decrease pulmonary vascular resistance/pressure by preventing the breakdown of cGMP.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphodiesterase type 5A (PDE5A).